Following treatment with ATO, myeloma cell lines with varying p53 status, all showed upregulation of DR4 and DR5 and synergy with TRAIL (Akay and Gazitt, 2003; Liu et al, 2003). This evidence concerns the gene TNFRSF10A and plasma cell myeloma.